RELATED CME CONTENT

Biologic Therapies IV

PML and Biologics -
State of the Art

	How to Obtain AMA PRA Category 1 Credit™ Watch the webcast. Complete the CME posttest (each question must be answered correctly). Login to your account. Complete the credit and evaluation form. Print your personalized CME certificate. Technical Requirements

Release Date:  June 24, 2011
Expiration Date:  June 24, 2013

Estimated Time of Completion:  30 minutes

Description

Biologic Therapies IV: Webcast Series is a compilation of live presentations recorded at the Biologic Therapies Summit IV: Current and Emerging Indications. This webcast series continues a successful tradition of presenting innovative, quality presentations that provide evidence-based, practical knowledge to fulfill participants' educational objectives. An international faculty of experts who span a multitude of scientific disciplines will provide their insights on a variety of timely topics, including the following:

• Research advances in immunodeficiencies and autoimmunity,
• Approved biologic agents and clinical trial data,
• Development of new biologic agents,
• Toxicities associated with biologic agents,
• Clinical implications and potential new indications.

Learning Objectives

• Update the concept of immune privilege of the CNS.
• Communicate the cellular basis of immune surveillance of the CNS.
• Integrate knowledge about mechanisms of action of biologics associated with PML into the concepts of immune privilege and immune surveillance of the CNS.

Target Audience

This activity is directed to rheumatologists, gastroenterologists, dermatologists, pulmonologists, internal medicine physicians, nurse practitioners, physician assistants, and other health care professionals interested in or using biologic therapies in autoimmune and inflammatory disorders.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.

Activity Director

Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Faculty

Richard M. Ransohoff, MD
Professor of Molecular Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Neuroinflammation Research Center
Lerner Research Institute
Mellen MS Center
Neurological Institute
Cleveland, OH

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational
grants for partial support of this activity from:

Abbott Laboratories Inc.,
Amgen, Inc.,
Bristol-Myers Squibb,
Centocor Ortho Biotech Services, LLC,
Genentech, Inc. and Biogen Idec,
UCB, Inc.

This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education and the
R.J. Fasenmyer Center for Clinical Immunology.

CME Disclaimer